2024 年第 6 期 第 0 卷

枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征效果和安全性的Meta分析

Meta-analysis of the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome

作者：魏启鲁1张双2张向荣2张俊海3张艳丽1杜时雨1

英文作者：Wei Qilu1 Zhang Shuang2 Zhang Xiangrong2 Zhang Junhai3 Zhang Yanli1 Du Shiyu1

单位：1中日友好医院消化科，北京100029；2北京中医药大学，北京100029；3北京大学医学部，北京100191

英文单位：1Department of Gastroenterology China-Japan Friendship Hospital Beijing 100029 China; 2Beijing University of Chinese Medicine Beijing 100029 China; 3Peking University Health Science Center Beijing 100191 China

关键词：肠易激综合征；枯草杆菌二联活菌肠溶胶囊；Meta分析

英文关键词：Irritablebowelsyndrome;Livecombinedbacillussubtilisenteric-coatedcapsules;Meta-analysis

• 摘要：

• 目的 采用Meta分析方法评价枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征（IBS）的效果及安全性。方法 系统检索了PubMed、Embase、中国生物医学文献、中国知网、万方、维普、Cochrane Library等数据库，检索时间截止至2023年6月。观察组采用枯草杆菌二联活菌肠溶胶囊单用或联合其他药物治疗，对照组采用其他药物单药或联合治疗。利用RevMan 5.4.1软件进行Meta分析。结果 Meta分析结果显示，观察组总有效率优于对照组（相对危险度=1.20，P＜0.001），腹痛、腹泻症状发生率均低于对照组（均P＜0.05），而2组不良反应发生率差异无统计学意义（比值比=0.80，P=0.28）。亚组分析结果显示，观察组腹泻型IBS和便秘型IBS患者的治疗总有效率均高于对照组（均P＜0.05）。结论 基于目前的文献证据，枯草杆菌二联活菌肠溶胶囊治疗IBS有效性及安全性均较好。

• Objective To evaluate the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome (IBS) by Meta-analysis. Methods PubMed, Embase, CBM, CNKI, Wanfang, VIP, Cochrane Library and other databases were systematically searched until June 2023. The observation group was treated with live combined bacillus subtilis enteric-coated capsules alone or combined with other drugs, and the control group was treated with other drugs alone or combined. RevMan 5.4.1 software was used for Meta-analysis. Results Meta-analysis showed that the total effective rate of the observation group was better than that of the control group (relative risk=1.20, P＜0.001), and the incidences of abdominal pain and diarrhea symptoms were lower than those of the control group (all P＜0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups (odds ratio=0.80, P=0.28). Subgroup analysis showed that the total effective rates of the observation group were higher than those of the control group in diarrhea-predominant IBS and constipation-predominant IBS (both P＜0.05). Conclusion Based on the current literature evidence, live combined bacillus subtilis enteric-coated capsules are effective and safe in the treatment of IBS.